–
/ By Clive Minchom /
Pharmaceutical company Kamada Ltd. (TASE: KMDA) filed a preliminary prospectus for an offering on Nasdaq with the US Securities and Exchange 
Commission (SEC) on Friday. Morgan Stanley & Co. LLC and Jefferies LLC are the underwriters. No pricing terms were disclosed.
Commission (SEC) on Friday. Morgan Stanley & Co. LLC and Jefferies LLC are the underwriters. No pricing terms were disclosed.The preliminary prospectus has not yet come into effect, and it is not binding on the company to hold an offering.
Earlier this month, Kamada guided for $74 million revenue in 2013, up from $73 million in 2012.
Kamada, which produces plasma-derived protein therapeutics, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company’s shares are already listed on the Tel Aviv Stock Exchange under the symbol KMDA.
